PerkinElmer Announces Financial Results for the Second Quarter of 2019

  • Revenue of $722.5 million; 3% Reported growth; Organic growth of 5%
  • GAAP EPS from continuing operations of $0.62; Adjusted EPS of $1.00
  • GAAP operating income margin from continuing operations of 12.7%; Adjusted operating income margin from continuing operations of 20.2%. Strong operating margin improvement year-to-date.
  • Updating GAAP EPS guidance range to $2.61 to $2.66; Reiterating adjusted EPS guidance range of $4.02 to $4.07

WALTHAM, Mass.–(BUSINESS WIRE)–$PKIPerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended June 30, 2019.

The Company reported GAAP earnings per share from continuing operations of $0.62, as compared to GAAP earnings per share from continuing operations of $0.58 in the second quarter of 2018. GAAP revenue for the quarter was $722.5 million, as compared to $703.4 million in the second quarter of 2018. GAAP operating income from continuing operations for the quarter was $91.7 million, as compared to $88.1 million in the second quarter of 2018. GAAP operating profit margin was 12.7% as a percentage of revenue, as compared to 12.5% in the second quarter of 2018.

Adjusted earnings per share from continuing operations for the quarter was $1.00, as compared to $0.91 in the second quarter of 2018. Adjusted revenue for the quarter was $722.7 million, as compared to $703.6 million in the second quarter of 2018. Adjusted operating income from continuing operations for the quarter was $146.0 million, as compared to $138.3 million for the same period a year ago. Adjusted operating profit margin was 20.2% as a percentage of adjusted revenues, as compared to 19.7% in the second quarter of 2018.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

I am very pleased with our second quarter performance as we continued to make significant progress against our key long-term priorities while also generating mid-single digit organic revenue growth and double-digit adjusted EPS growth,” said Robert Friel, chairman and chief executive officer of PerkinElmer. “The actions we are taking not only position us for a strong finish to 2019 but further evolve the company to deliver higher growth, greater resiliency and increased profitability.”

Financial Overview by Reporting Segment for the Second Quarter of 2019

Discovery & Analytical Solutions

  • Revenue was $434.0 million, as compared to $430.6 million for the second quarter of 2018. Reported revenue increased 1% and organic revenue increased 2%.
  • Operating income from continuing operations was $57.7 million, as compared to $64.7 million for the comparable prior period.
  • Adjusted operating income was $81.5 million, as compared to $76.4 million in the second quarter of 2018.

Diagnostics

  • Revenue was $288.6 million, as compared to $272.7 million for the second quarter of 2018. Reported revenue increased 6% and organic revenue increased 9%.
  • Operating income from continuing operations was $49.3 million, as compared to $38.8 million for the comparable prior period.
  • Adjusted operating income was $79.7 million, as compared to $77.2 million in the second quarter of 2018.

Full Year 2019 Guidance

For the full year 2019, the Company now forecasts GAAP earnings per share from continuing operations in a range of $2.61 to $2.66 and, on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliations, adjusted earnings per share of $4.02 to $4.07.

Conference Call Information

The Company will discuss its second quarter 2019 results and its outlook for business trends in a conference call on July 29, 2019 at 5:00 p.m. Eastern Time. To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 2774907.

A live audio webcast of the call will be available on the Investors section of the Company’s website, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s website for a two-week period beginning approximately two hours after the call.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems, or cybercrime; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the United Kingdom’s intention to withdraw from the European Union; (21) our ability to realize the full value of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.8 billion in 2018, has about 13,000 employees serving customers in more than 180 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

 
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
 
 

Three Months Ended

Six Months Ended

(In thousands, except per share data) June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018
 
 
Revenue

$

722,517

 

$

703,362

 

$

1,371,254

 

$

1,347,334

 

 
Cost of revenue

 

374,724

 

 

363,222

 

 

715,655

 

 

714,972

 

Selling, general and administrative expenses

 

201,553

 

 

204,880

 

 

400,410

 

 

404,605

 

Research and development expenses

 

48,344

 

 

47,196

 

 

96,324

 

 

93,180

 

Restructuring and contract termination charges, net

 

6,161

 

 

 

 

13,800

 

 

6,578

 

 
Operating income from continuing operations

 

91,735

 

 

88,064

 

 

145,065

 

 

127,999

 

 
Interest income

 

(350

)

 

(173

)

 

(633

)

 

(438

)

Interest expense

 

17,207

 

 

16,411

 

 

33,057

 

 

34,061

 

Loss on disposition of businesses and assets, net

 

336

 

 

 

 

2,469

 

 

 

Other expense (income), net

 

2,715

 

 

118

 

 

1,580

 

 

(5,837

)

 
Income from continuing operations, before income taxes

 

71,827

 

 

71,708

 

 

108,592

 

 

100,213

 

 
Provision for income taxes

 

2,686

 

 

7,035

 

 

3,998

 

 

9,505

 

 
Income from continuing operations

 

69,141

 

 

64,673

 

 

104,594

 

 

90,708

 

 
Loss on disposition of discontinued operations, before income taxes

 

 

 

(551

)

 

 

 

(551

)

Provision for income taxes on discontinued operations and dispositions

 

54

 

 

59

 

 

95

 

 

70

 

 
Loss from discontinued operations and dispositions

 

(54

)

 

(610

)

 

(95

)

 

(621

)

 
Net income

$

69,087

 

$

64,063

 

$

104,499

 

$

90,087

 

 
 
Diluted earnings per share:
Income from continuing operations

$

0.62

 

$

0.58

 

$

0.94

 

$

0.81

 

 
Loss from discontinued operations and dispositions

 

(0.00

)

 

(0.01

)

 

(0.00

)

 

(0.01

)

 
Net income

$

0.62

 

$

0.57

 

$

0.94

 

$

0.81

 

 
 
Weighted average diluted shares of common stock outstanding

 

111,528

 

 

111,452

 

 

111,411

 

 

111,391

 

 
 
ABOVE PREPARED IN ACCORDANCE WITH GAAP
 
 
Additional Supplemental Information (1):
(per share, continuing operations)
 
GAAP EPS from continuing operations

 

0.62

 

 

0.58

 

 

0.94

 

 

0.81

 

Amortization of intangible assets

 

0.37

 

 

0.29

 

 

0.72

 

 

0.59

 

Purchase accounting adjustments

 

0.05

 

 

0.14

 

 

0.08

 

 

0.23

 

Significant litigation matter

 

0.00

 

 

(0.00

)

 

0.01

 

 

0.04

 

Acquisition and divestiture-related costs

 

0.03

 

 

0.02

 

 

0.05

 

 

0.03

 

Disposition of businesses and assets, net

 

0.00

 

 

 

 

0.02

 

 

 

Restructuring and contract termination charges, net

 

0.06

 

 

 

 

0.12

 

 

0.06

 

Tax on above items

 

(0.13

)

 

(0.12

)

 

(0.25

)

 

(0.24

)

Impact of tax act

 

 

 

 

 

 

 

0.01

 

Adjusted EPS

 

1.00

 

 

0.91

 

 

1.69

 

 

1.54

 

 
(1) amounts may not sum due to rounding
 
 
 
PerkinElmer, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
 
 
 

Three Months Ended

Six Months Ended

(In thousands, except percentages)

June 30, 2019

July 1, 2018

June 30, 2019

July 1, 2018

 
 
DAS Reported revenue

$

 

433,967

 

$

 

430,628

 

$

 

822,800

 

$

 

827,153

 

 
Reported operating income from continued operations

57,689

 

64,665

 

94,616

 

100,862

 

OP%

13.3

%

15.0

%

11.5

%

12.2

%

Amortization of intangible assets

13,113

 

11,472

 

23,382

 

23,183

 

Purchase accounting adjustments

5,014

 

15

 

5,051

 

30

 

Acquisition and divestiture-related costs

416

 

33

 

959

 

71

 

Significant litigation matter

439

 

232

 

815

 

4,417

 

Restructuring and contract termination charges, net

4,820

 

 

11,000

 

5,676

 

Adjusted operating income

81,491

 

76,417

 

135,823

 

134,239

 

Adjusted OP%

18.8

%

17.7

%

16.5

%

16.2

%

 
Diagnostics Reported revenue

288,550

 

272,734

 

548,454

 

520,181

 

Purchase accounting adjustments

192

 

188

 

384

 

375

 

Adjusted revenue

288,742

 

272,922

 

548,838

 

520,556

 

 
Reported operating income from continued operations

49,255

 

38,780

 

80,741

 

57,174

 

OP%

17.1

%

14.2

%

14.7

%

11.0

%

Amortization of intangible assets

28,089

 

21,045

 

56,547

 

42,234

 

Purchase accounting adjustments

516

 

16,103

 

4,087

 

25,631

 

Acquisition and divestiture-related costs

478

 

1,616

 

1,485

 

4,151

 

Significant litigation matter

 

(322

)

 

(172

)

Restructuring and contract termination charges, net

1,341

 

 

2,800

 

902

 

Adjusted operating income

79,679

 

77,222

 

145,660

 

129,920

 

Adjusted OP%

27.6

%

28.3

%

26.5

%

25.0

%

 
Corporate Reported operating loss

(15,209

)

(15,381

)

(30,292

)

(30,037

)

 
Continuing Operations Reported revenue

$

 

722,517

 

$

 

703,362

 

$

 

1,371,254

 

$

 

1,347,334

 

Purchase accounting adjustments

192

 

188

 

384

 

375

 

Adjusted revenue

722,709

 

703,550

 

1,371,638

 

1,347,709

 

 
Reported operating income from continued operations

91,735

 

88,064

 

145,065

 

127,999

 

OP%

12.7

%

12.5

%

10.6

%

9.5

%

Amortization of intangible assets

41,202

 

32,517

 

79,929

 

65,417

 

Purchase accounting adjustments

5,530

 

16,118

 

9,138

 

25,661

 

Acquisition and divestiture-related costs

894

 

1,649

 

2,444

 

4,222

 

Significant litigation matter

439

 

(90

)

815

 

4,245

 

Restructuring and contract termination charges, net

6,161

 

 

13,800

 

6,578

 

Adjusted operating income

$

 

145,961

 

$

 

138,258

 

$

 

251,191

 

$

 

234,122

 

Adjusted OP%

20.2

%

19.7

%

18.3

%

17.4

%

 
 

REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

 
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
 
(In thousands) June 30, 2019 December 30, 2018
 
Current assets:
Cash and cash equivalents

$

150,016

 

$

163,111

 

Accounts receivable, net

 

654,454

 

 

632,669

 

Inventories, net

 

414,330

 

 

338,347

 

Other current assets

 

118,961

 

 

100,507

 

Total current assets

 

1,337,761

 

 

1,234,634

 

 
Property, plant and equipment:
At cost

 

670,821

 

 

680,183

 

Accumulated depreciation

 

(368,101

)

 

(361,593

)

Property, plant and equipment, net

 

302,720

 

 

318,590

 

 
Operating lease right-of-use assets

 

187,934

 

 

 

Intangible assets, net

 

1,282,440

 

 

1,199,667

 

Goodwill

 

3,042,049

 

 

2,952,608

 

Other assets, net

 

246,168

 

 

270,023

 

Total assets

$

6,399,072

 

$

5,975,522

 

 
Current liabilities:
Current portion of long-term debt

$

38,043

 

$

14,856

 

Accounts payable

 

188,051

 

 

220,949

 

Short-term accrued restructuring and contract termination charges

 

10,987

 

 

4,834

 

Accrued expenses and other current liabilities

 

497,426

 

 

528,827

 

Current liabilities of discontinued operations

 

2,130

 

 

2,165

 

Total current liabilities

 

736,637

 

 

771,631

 

 
Long-term debt

 

2,074,628

 

 

1,876,624

 

Long-term liabilities

 

716,929

 

 

742,312

 

Operating lease liabilities

 

164,011

 

 

 

Total liabilities

 

3,692,205

 

 

3,390,567

 

 
Total stockholders’ equity

 

2,706,867

 

 

2,584,955

 

Total liabilities and stockholders’ equity

$

6,399,072

 

$

5,975,522

 

 
 
PREPARED IN ACCORDANCE WITH GAAP
 
PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
 

Three Months Ended

Six Months Ended

June 30, 2019

July 1, 2018

June 30, 2019

July 1, 2018

(In thousands)

(In thousands)

 
Operating activities:
Net income

$

69,087

 

$

64,063

 

$

104,499

 

$

90,087

 

Loss from discontinued operations and dispositions, net of income taxes

 

54

 

 

610

 

 

95

 

 

621

 

Income from continuing operations

 

69,141

 

 

64,673

 

 

104,594

 

 

90,708

 

Adjustments to reconcile income from continuing operations
to net cash provided by continuing operations:
Stock-based compensation

 

6,703

 

 

6,816

 

 

12,801

 

 

12,148

 

Restructuring and contract termination charges, net

 

6,161

 

 

 

 

13,800

 

 

6,578

 

Depreciation and amortization

 

53,324

 

 

43,772

 

 

103,793

 

 

88,225

 

Change in fair value of contingent consideration

 

59

 

 

6,948

 

 

3,161

 

 

7,065

 

Amortization of deferred debt financing costs and accretion of discounts

 

929

 

 

904

 

 

1,790

 

 

1,519

 

Loss on disposition of businesses and assets, net

 

336

 

 

 

 

2,469

 

 

 

Amortization of acquired inventory revaluation

 

5,282

 

 

8,952

 

 

5,565

 

 

18,160

 

Changes in assets and liabilities which provided (used) cash, excluding
effects from companies acquired:
Accounts receivable, net

 

(17,468

)

 

(8,488

)

 

(9,604

)

 

(18,768

)

Inventories

 

(12,009

)

 

(17,965

)

 

(50,450

)

 

(42,993

)

Accounts payable

 

(38,500

)

 

(14,358

)

 

(39,951

)

 

(24,384

)

Accrued expenses and other

 

(27,100

)

 

(18,268

)

 

(106,425

)

 

(79,831

)

Net cash provided by operating activities of continuing operations

 

46,858

 

 

72,986

 

 

41,543

 

 

58,427

 

Net cash used in operating activities of discontinued operations

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

46,858

 

 

72,986

 

 

41,543

 

 

58,427

 

 
Investing activities:
Capital expenditures

 

(16,586

)

 

(16,956

)

 

(36,461

)

 

(39,608

)

Purchases of investments

 

(348

)

 

 

 

(868

)

 

 

Purchases of licenses

 

 

 

 

 

(5,000

)

 

 

Proceeds from surrender of life insurance policies

 

 

 

 

 

 

 

72

 

Proceeds from disposition of businesses and assets

 

 

 

173

 

 

550

 

 

173

 

Payment of acquisitions, net of cash and cash equivalents acquired

 

(240,354

)

 

(39,470

)

 

(244,738

)

 

(40,557

)

Net cash used in investing activities of continuing operations

 

(257,288

)

 

(56,253

)

 

(286,517

)

 

(79,920

)

Net cash provided by investing activities of discontinued operations

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

(257,288

)

 

(56,253

)

 

(286,517

)

 

(79,920

)

 
Financing Activities:
Payments on borrowings

 

(426,000

)

 

(520,000

)

 

(578,000

)

 

(667,000

)

Proceeds from borrowings

 

670,550

 

 

138,000

 

 

849,550

 

 

342,000

 

Proceeds from sale of senior debt

 

 

 

369,340

 

 

 

 

369,340

 

Payments of debt issuance costs

 

(93

)

 

(2,634

)

 

(181

)

 

(2,634

)

Settlement of cash flow hedges

 

16

 

 

3,458

 

 

(1,659

)

 

(32,711

)

Net payments on other credit facilities

 

(6,330

)

 

(7,147

)

 

(9,806

)

 

(10,154

)

Payments for acquisition-related contingent consideration

 

(11,600

)

 

 

 

(23,700

)

 

 

Proceeds from issuance of common stock under stock plans

 

7,944

 

 

881

 

 

16,554

 

 

8,348

 

Purchases of common stock

 

(764

)

 

(95

)

 

(6,057

)

 

(4,649

)

Dividends paid

 

(7,764

)

 

(7,744

)

 

(15,507

)

 

(15,471

)

Net cash provided by (used in) financing activities of continuing operations

 

225,959

 

 

(25,941

)

 

231,194

 

 

(12,931

)

Net cash used in financing activities of discontinued operations

 

 

 

 

 

 

 

 

Net cash provided by (used in) financing activities

 

225,959

 

 

(25,941

)

 

231,194

 

 

(12,931

)

 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

235

 

 

(8,201

)

 

685

 

 

(4,351

)

 
Net increase (decrease) in cash, cash equivalents, and restricted cash

 

15,764

 

 

(17,409

)

 

(13,095

)

 

(38,775

)

Cash, cash equivalents, and restricted cash at beginning of period

 

137,456

 

 

181,005

 

 

166,315

 

 

202,371

 

Cash, cash equivalents, and restricted cash at end of period

$

153,220

 

$

163,596

 

$

153,220

 

$

163,596

 

 
 
Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents

 

150,016

 

$

163,392

 

 

150,016

 

$

163,392

 

Restricted cash included in other current assets

 

3,204

 

 

204

 

 

3,204

 

 

204

 

Total cash, cash equivalents and restricted cash

$

153,220

 

$

163,596

 

$

153,220

 

$

163,596

 

 
PREPARED IN ACCORDANCE WITH GAAP
 
 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
 
(In millions, except per share data and percentages) PKI

Three Months Ended

June 30, 2019

July 1, 2018

 
Adjusted revenue:
Revenue

$

 

722.5

 

$

 

703.4

 

Purchase accounting adjustments

 

0.2

 

 

0.2

 

Adjusted revenue

$

 

722.7

 

$

 

703.6

 

 
Adjusted gross margin:
Gross margin

$

 

347.8

 

48.1

%

$

 

340.1

 

48.4

%

Amortization of intangible assets

 

15.6

 

2.2

%

 

11.6

 

1.6

%

Purchase accounting adjustments

 

5.5

 

0.8

%

 

9.2

 

1.3

%

Adjusted gross margin

$

 

368.9

 

51.0

%

$

 

360.9

 

51.3

%

 
Adjusted SG&A:
SG&A

$

 

201.6

 

27.9

%

$

 

204.9

 

29.1

%

Amortization of intangible assets

 

(25.6

)

-3.5

%

 

(20.9

)

-3.0

%

Purchase accounting adjustments

 

(0.1

)

0.0

%

 

(7.0

)

-1.0

%

Acquisition and divestiture-related expenses

 

(0.9

)

-0.1

%

 

(1.6

)

-0.2

%

Significant litigation matter

 

(0.4

)

-0.1

%

 

0.1

 

0.0

%

Adjusted SG&A

$

 

174.6

 

24.2

%

$

 

175.5

 

24.9

%

 
Adjusted R&D:
R&D

$

 

48.3

 

6.7

%

$

 

47.2

 

6.7

%

Amortization of intangible assets

 

0.0

%

 

(0.1

)

0.0

%

Adjusted R&D

$

 

48.3

 

6.7

%

$

 

47.1

 

6.7

%

 
Adjusted operating income:
Operating income

$

 

91.7

 

12.7

%

$

 

88.1

 

12.5

%

Amortization of intangible assets

 

41.2

 

5.7

%

 

32.5

 

4.6

%

Purchase accounting adjustments

 

5.5

 

0.8

%

 

16.1

 

2.3

%

Acquisition and divestiture-related expenses

 

0.9

 

0.1

%

 

1.6

 

0.2

%

Significant litigation matter

 

0.4

 

0.1

%

 

(0.1

)

0.0

%

Restructuring and contract termination charges, net

 

6.2

 

0.9

%

 

 

0.0

%

Adjusted operating income

$

 

146.0

 

20.2

%

$

 

138.3

 

19.7

%

 
PKI

Three Months Ended

June 30, 2019

July 1, 2018

 
Adjusted EPS:
GAAP EPS

$

 

0.62

 

$

 

0.57

 

Discontinued operations, net of income taxes

 

(0.00

)

 

(0.01

)

GAAP EPS from continuing operations

 

0.62

 

 

0.58

 

Amortization of intangible assets

 

0.37

 

 

0.29

 

Purchase accounting adjustments

 

0.05

 

 

0.14

 

Significant litigation matter

 

0.00

 

 

(0.00

)

Acquisition and divestiture-related expenses

 

0.03

 

 

0.02

 

Gain on disposition of businesses and assets, net

 

0.00

 

 

 

Restructuring and contract termination charges, net

 

0.06

 

 

 

Tax on above items

 

(0.13

)

 

(0.12

)

Adjusted EPS

$

 

1.00

 

$

 

0.91

 

 

DAS

Three Months Ended

June 30, 2019

July 1, 2018

 
Revenue

$

 

434.0

 

$

 

430.6

 

 
Adjusted operating income:
Operating income

$

 

57.7

 

13.3

%

$

 

64.7

 

15.0

%

Amortization of intangible assets

 

13.1

 

3.0

%

 

11.5

 

2.7

%

Purchase accounting adjustments

 

5.0

 

1.2

%

 

0.0

 

0.0

%

Acquisition and divestiture-related expenses

 

0.4

 

0.1

%

 

0.0

 

0.0

%

Significant litigation matter

 

0.4

 

0.1

%

 

0.2

 

0.1

%

Restructuring and contract termination charges, net

 

4.8

 

1.1

%

 

 

0.0

%

Adjusted operating income

$

 

81.5

 

18.8

%

$

 

76.4

 

17.7

%

 

Diagnostics

Three Months Ended

June 30, 2019

July 1, 2018

 
Adjusted revenue:
Revenue

$

 

288.6

 

$

 

272.7

 

Purchase accounting adjustments

 

0.2

 

 

0.2

 

Adjusted revenue

$

 

288.7

 

$

 

272.9

 

 
Adjusted operating income:
Operating income

$

 

49.3

 

17.1

%

$

 

38.8

 

14.2

%

Amortization of intangible assets

 

28.1

 

9.7

%

 

21.0

 

7.7

%

Purchase accounting adjustments

 

0.5

 

0.2

%

 

16.1

 

5.9

%

Acquisition and divestiture-related expenses

 

0.5

 

0.2

%

 

1.6

 

0.6

%

Significant litigation matter

 

 

0.0

%

 

(0.3

)

-0.1

%

Restructuring and contract termination charges, net

 

1.3

 

0.5

%

 

 

0.0

%

Adjusted operating income

$

 

79.7

 

27.6

%

$

 

77.2

 

28.3

%

 
 
(1) amounts may not sum due to rounding
 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
 
(In millions, except per share data and percentages) PKI

Six Months Ended

June 30, 2019

July 1, 2018

 
Adjusted revenue:
Revenue

$

1,371.3

 

$

1,347.3

 

Purchase accounting adjustments

 

0.4

 

 

0.4

 

Adjusted revenue

$

1,371.6

 

$

1,347.7

 

 
Adjusted gross margin:
Gross margin

$

655.6

 

47.8

%

$

632.4

 

46.9

%

Amortization of intangible assets

 

30.4

 

2.2

%

 

23.3

 

1.7

%

Purchase accounting adjustments

 

6.0

 

0.4

%

 

18.6

 

1.4

%

Adjusted gross margin

$

692.0

 

50.5

%

$

674.2

 

50.0

%

 
Adjusted SG&A:
SG&A

$

400.4

 

29.2

%

$

404.6

 

30.0

%

Amortization of intangible assets

 

(49.5

)

-3.6

%

 

(42.0

)

-3.1

%

Purchase accounting adjustments

 

(3.2

)

-0.2

%

 

(7.1

)

-0.5

%

Acquisition and divestiture-related expenses

 

(2.4

)

-0.2

%

 

(4.2

)

-0.3

%

Significant litigation matter

 

(0.8

)

-0.1

%

 

(4.2

)

-0.3

%

Adjusted SG&A

$

344.5

 

25.1

%

$

347.0

 

25.8

%

 
Adjusted R&D:
R&D

$

96.3

 

7.0

%

$

93.2

 

6.9

%

Amortization of intangible assets

 

 

0.0

%

 

(0.2

)

0.0

%

Adjusted R&D

$

96.3

 

7.0

%

$

93.0

 

6.9

%

 
Adjusted operating income:
Operating income

$

145.1

 

10.6

%

$

128.0

 

9.5

%

Amortization of intangible assets

 

79.9

 

5.8

%

 

65.4

 

4.9

%

Purchase accounting adjustments

 

9.1

 

0.7

%

 

25.7

 

1.9

%

Acquisition and divestiture-related expenses

 

2.4

 

0.2

%

 

4.2

 

0.3

%

Significant litigation matter

 

0.8

 

0.1

%

 

4.2

 

0.3

%

Restructuring and contract termination charges, net

 

13.8

 

1.0

%

 

6.6

 

0.5

%

Adjusted operating income

$

251.2

 

18.3

%

$

234.1

 

17.4

%

 
PKI

Six Months Ended

June 30, 2019

July 1, 2018

 
Adjusted EPS:
GAAP EPS

$

0.94

 

$

0.81

 

Discontinued operations

 

(0.00

)

 

(0.01

)

GAAP EPS from continuing operations

 

0.94

 

 

0.81

 

Amortization of intangible assets

 

0.72

 

 

0.59

 

Purchase accounting adjustments

 

0.08

 

 

0.23

 

Significant litigation matter

 

0.01

 

 

0.04

 

Acquisition and divestiture-related expenses

 

0.05

 

 

0.03

 

Gain on disposition of businesses and assets, net

 

0.02

 

 

 

Restructuring and contract termination charges, net

 

0.12

 

 

0.06

 

Tax on above items

 

(0.25

)

 

(0.24

)

Impact of tax act

 

 

 

0.01

 

Adjusted EPS

$

1.69

 

$

1.54

 

 
PKI

Twelve Months Ended

December 29, 2019

Adjusted EPS:

Projected

GAAP EPS from continuing operations $2.61 – $2.66
Amortization of intangible assets

 

1.47

 

Purchase accounting adjustments

 

0.23

 

Significant litigation matter

 

0.01

 

Acquisition and divestiture-related expenses

 

0.05

 

Disposition of businesses and assets, net

 

0.02

 

Restructuring and contract termination charges, net

 

0.12

 

Tax on above items

 

(0.49

)

Adjusted EPS $4.02 – $4.07
 
DAS

Six Months Ended

June 30, 2019

July 1, 2018

 
Revenue

$

822.8

 

$

827.2

 

 
Adjusted operating income:
Operating income

$

94.6

 

11.5

%

$

100.9

 

12.2

%

Amortization of intangible assets

 

23.4

 

2.8

%

 

23.2

 

2.8

%

Purchase accounting adjustments

 

5.1

 

0.6

%

 

0.0

 

0.0

%

Acquisition and divestiture-related expenses

 

1.0

 

0.1

%

 

0.1

 

0.0

%

Significant litigation matter

 

0.8

 

0.1

%

 

4.4

 

0.5

%

Restructuring and contract termination charges, net

 

11.0

 

1.3

%

 

5.7

 

0.7

%

Adjusted operating income

$

135.8

 

16.5

%

$

134.2

 

16.2

%

 
Diagnostics

Six Months Ended

June 30, 2019

July 1, 2018

 
Adjusted revenue:
Revenue

$

548.5

 

$

520.2

 

Purchase accounting adjustments

 

0.4

 

 

0.4

 

Adjusted revenue

$

548.8

 

$

520.6

 

 
Adjusted operating income:
Operating income

$

80.7

 

14.7

%

$

57.2

 

11.0

%

Amortization of intangible assets

 

56.5

 

10.3

%

 

42.2

 

8.1

%

Purchase accounting adjustments

 

4.1

 

0.7

%

 

25.6

 

4.9

%

Acquisition and divestiture-related expenses

 

1.5

 

0.3

%

 

4.2

 

0.8

%

Significant litigation matter

 

 

0.0

%

 

(0.2

)

0.0

%

Restructuring and contract termination charges, net

 

2.8

 

0.5

%

 

0.9

 

0.2

%

Adjusted operating income

$

145.7

 

26.5

%

$

129.9

 

25.0

%

 
 
(1) amounts may not sum due to rounding
 

Contacts

Investor Relations:

PerkinElmer, Inc.

Bryan Kipp (781) 663-5583

bryan.kipp@perkinelmer.com


Media Contact:

PerkinElmer, Inc.

Fara Goldberg (781) 663-5699

fara.goldberg@perkinelmer.com

Read full story here

error: Content is protected !!